Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: Tirzepatide, Mounjaro, Zepbound
A dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with weight-loss results that often exceed GLP-1-only agents.
Sign in to rate this peptide.
Tirzepatide is a single peptide that activates both the GIP and GLP-1 incretin receptors. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while GIP agonism is thought to further improve insulin sensitivity and lipid metabolism. This dual incretin action produces robust glycemic and weight effects, with fatty-acid acylation enabling once-weekly dosing.